Company
Amylyx Pharmaceuticals
Ushering in a new era for treating diseases with high unmet needs
Also known as Amylyx, Amylyx Pharmaceuticals, Inc.
- Business model
- B2B
- Legal name
- Amylyx Pharmaceuticals, Inc.
- amylyx.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see obstacles, the Amylyx team sees opportunities to find solutions for some of medicine’s toughest challenges.
Funding snapshot
- Total raised
- $65.1MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $30M2020-06-18
Funding rounds
- Round, 2020
- $30M2020-06-18, SEC form D sold, 17 investors
- Round, 2019
- $14.8M2019-12-17, SEC form D sold, 37 investors
- Round, 2018
- $13M2018-11-14, SEC form D sold, 32 investors
- Round, 2017
- $1.8M2017-07-31, SEC form D sold, 30 investors
- Round, 2016
- $4.1M2016-08-08, SEC form D sold, 19 investors
- Round, 2014
- $1.4M2014-03-05, SEC form D sold, 28 investors
About the company
- Status notes
- Commercial-stage pharmaceutical company developing Relyvrio for amyotrophic lateral sclerosis
Products
- Web
- Avexitide
Loading relationship preview